> top > docs > PMC:7205724 > spans > 170-596 > annotations

PMC:7205724 / 170-596 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
3 82-89 Species denotes patient Tax:9606
5 161-169 Disease denotes COVID-19 MESH:C000657245
7 244-252 Disease denotes COVID-19 MESH:C000657245
10 257-260 Gene denotes IL6 Gene:3569
11 329-337 Disease denotes COVID-19 MESH:C000657245
17 363-366 Gene denotes IL6 Gene:3569
18 422-425 Gene denotes IL6 Gene:3569
19 390-398 Species denotes patients Tax:9606
20 342-353 Chemical denotes Tocilizumab MESH:C502936
21 404-412 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T2 161-169 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T3 244-252 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 329-337 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 404-412 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T3 51-66 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858
T4 114-129 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858
T5 224-239 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858

LitCovid-sample-MedDRA

Id Subject Object Predicate Lexical cue meddra_id
T2 300-310 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes viral load http://purl.bioontology.org/ontology/MEDDRA/10062178

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T2 51-66 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858
T3 114-129 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858
T4 224-239 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T2 161-169 Species denotes COVID-19 NCBItxid:2697049
T3 244-252 Species denotes COVID-19 NCBItxid:2697049
T4 329-337 Species denotes COVID-19 NCBItxid:2697049
T5 404-412 Species denotes COVID-19 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T4 0-10 Sentence denotes Highlights
T5 11-99 Sentence denotes • IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes.
T6 100-170 Sentence denotes • The use of corticosteroids might accelerate recovery from COVID-19.
T7 171-253 Sentence denotes • No controlled clinical trials exist on the use of corticosteroids for COVID-19.
T8 254-338 Sentence denotes • IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.
T9 339-426 Sentence denotes • Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
3 82-89 Species denotes patient Tax:9606
5 161-169 Disease denotes COVID-19 MESH:C000657245
7 244-252 Disease denotes COVID-19 MESH:C000657245
10 257-260 Gene denotes IL6 Gene:3569
11 329-337 Disease denotes COVID-19 MESH:C000657245
20 342-353 Chemical denotes Tocilizumab MESH:C502936
17 363-366 Gene denotes IL6 Gene:3569
19 390-398 Species denotes patients Tax:9606
21 404-412 Disease denotes COVID-19 MESH:C000657245
18 422-425 Gene denotes IL6 Gene:3569

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T1 257-260 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0
T45 363-366 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0
T89 422-425 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T23 0-10 NNS denotes Highlights
T24 11-12 IN denotes •
T25 14-18 NNP denotes IVIG
T26 18-19 -COMMA- denotes ,
T27 20-28 VBN denotes combined
T28 29-33 IN denotes with
T29 34-47 NN denotes moderate-dose
T30 48-50 IN denotes of
T31 51-66 NNS denotes corticosteroids
T32 66-67 -COMMA- denotes ,
T33 68-73 MD denotes might
T34 74-81 VB denotes improve
T35 82-89 NN denotes patient
T36 90-98 NNS denotes outcomes
T37 100-101 PDT denotes •
T38 103-106 DT denotes The
T39 107-110 NN denotes use
T40 111-113 IN denotes of
T41 114-129 NNS denotes corticosteroids
T42 130-135 MD denotes might
T43 136-146 VB denotes accelerate
T44 147-155 NN denotes recovery
T45 156-160 IN denotes from
T46 161-169 NN denotes COVID-19
T47 171-172 PDT denotes •
T48 174-176 DT denotes No
T49 177-187 VBN denotes controlled
T50 188-196 JJ denotes clinical
T51 197-203 NNS denotes trials
T52 204-209 VBP denotes exist
T53 210-212 IN denotes on
T54 213-216 DT denotes the
T55 217-220 NN denotes use
T56 221-223 IN denotes of
T57 224-239 NNS denotes corticosteroids
T58 240-243 IN denotes for
T59 244-252 NN denotes COVID-19
T60 254-255 LS denotes •
T61 257-260 NN denotes IL6
T62 261-271 VBZ denotes correlates
T63 272-276 IN denotes with
T64 277-285 NN denotes severity
T65 285-286 -COMMA- denotes ,
T66 287-298 NN denotes criticality
T67 298-299 -COMMA- denotes ,
T68 300-305 JJ denotes viral
T69 306-310 NN denotes load
T70 310-311 -COMMA- denotes ,
T71 312-315 CC denotes and
T72 316-325 NN denotes prognosis
T73 326-328 IN denotes of
T74 329-337 NN denotes COVID-19
T75 339-340 IN denotes •
T76 342-353 NNP denotes Tocilizumab
T77 353-354 -COMMA- denotes ,
T78 355-357 DT denotes an
T79 358-366 NN denotes anti-IL6
T80 366-367 -COMMA- denotes ,
T81 368-371 MD denotes can
T82 372-378 VB denotes confer
T83 379-386 NN denotes benefit
T84 387-389 IN denotes in
T85 390-398 NNS denotes patients
T86 399-403 IN denotes with
T87 404-412 NN denotes COVID-19
T88 413-416 CC denotes and
T89 417-421 JJ denotes high
T90 422-425 NN denotes IL6
R20 T25 T24 arg1Of IVIG,•
R21 T25 T26 arg1Of IVIG,","
R22 T25 T27 arg2Of IVIG,combined
R23 T27 T28 arg1Of combined,with
R24 T29 T28 arg2Of moderate-dose,with
R25 T29 T30 arg1Of moderate-dose,of
R26 T31 T30 arg2Of corticosteroids,of
R27 T34 T32 arg1Of improve,","
R28 T25 T33 arg1Of IVIG,might
R29 T34 T33 arg2Of improve,might
R30 T25 T34 arg1Of IVIG,improve
R31 T36 T34 arg2Of outcomes,improve
R32 T36 T35 arg1Of outcomes,patient
R33 T39 T37 arg1Of use,•
R34 T39 T38 arg1Of use,The
R35 T39 T40 arg1Of use,of
R36 T41 T40 arg2Of corticosteroids,of
R37 T39 T42 arg1Of use,might
R38 T43 T42 arg2Of accelerate,might
R39 T39 T43 arg1Of use,accelerate
R40 T44 T43 arg2Of recovery,accelerate
R41 T44 T45 arg1Of recovery,from
R42 T46 T45 arg2Of COVID-19,from
R43 T51 T47 arg1Of trials,•
R44 T51 T48 arg1Of trials,No
R45 T51 T49 arg2Of trials,controlled
R46 T51 T50 arg1Of trials,clinical
R47 T51 T52 arg1Of trials,exist
R48 T52 T53 arg1Of exist,on
R49 T55 T53 arg2Of use,on
R50 T55 T54 arg1Of use,the
R51 T55 T56 arg1Of use,of
R52 T57 T56 arg2Of corticosteroids,of
R53 T55 T58 arg1Of use,for
R54 T59 T58 arg2Of COVID-19,for
R55 T62 T60 arg1Of correlates,•
R56 T61 T62 arg1Of IL6,correlates
R57 T62 T63 arg1Of correlates,with
R58 T71 T63 arg2Of and,with
R59 T64 T65 arg1Of severity,","
R60 T66 T65 arg2Of criticality,","
R61 T65 T67 arg1Of ",",","
R62 T69 T67 arg2Of load,","
R63 T69 T68 arg1Of load,viral
R64 T71 T70 arg1Of and,","
R65 T67 T71 arg1Of ",",and
R66 T72 T71 arg2Of prognosis,and
R67 T72 T73 arg1Of prognosis,of
R68 T74 T73 arg2Of COVID-19,of
R69 T82 T75 arg1Of confer,•
R70 T76 T77 arg1Of Tocilizumab,","
R71 T79 T77 arg2Of anti-IL6,","
R72 T79 T78 arg1Of anti-IL6,an
R73 T82 T80 arg1Of confer,","
R74 T76 T81 arg1Of Tocilizumab,can
R75 T82 T81 arg2Of confer,can
R76 T76 T82 arg1Of Tocilizumab,confer
R77 T83 T82 arg2Of benefit,confer
R78 T82 T84 arg1Of confer,in
R79 T85 T84 arg2Of patients,in
R80 T85 T86 arg1Of patients,with
R81 T88 T86 arg2Of and,with
R82 T87 T88 arg1Of COVID-19,and
R83 T90 T88 arg2Of IL6,and
R84 T90 T89 arg1Of IL6,high

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T2 161-169 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T3 244-252 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 329-337 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 404-412 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T4 0-10 Sentence denotes Highlights
T5 11-99 Sentence denotes • IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes.
T6 100-170 Sentence denotes • The use of corticosteroids might accelerate recovery from COVID-19.
T7 171-253 Sentence denotes • No controlled clinical trials exist on the use of corticosteroids for COVID-19.
T8 254-338 Sentence denotes • IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.
T9 339-426 Sentence denotes • Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.